Navigation Links
VAI Findings Could Aid Diagnosis and Treatment of Several Types of Kidney Cancer
Date:9/12/2008

Van Andel Institute researchers are first to associate unique DNA changes

with several types of renal cell carcinoma

GRAND RAPIDS, Mich., Sept. 12 /PRNewswire/ -- Van Andel Institute (VAI) researchers have identified unique DNA changes in each of several types of renal cell carcinoma (RCC), the most common form of kidney cancer in adults. These findings could aid in the diagnosis of these cancers since the many types of RCC are currently identified only by their appearance. Further research could identify drug targets for each type of RCC.

"There are so many subtypes of RCC, and currently they are identified by sight, which can be subjective," said VAI Distinguished Scientific Investigator Bin Tean Teh, M.D., Ph.D., whose laboratory published the recent findings in Cancer Letters. "Now we have an objective, definitive way to identify several types of RCC, which could have diagnostic and prognostic value."

The researchers found DNA changes specific to type 1 and 2 papillary RCC, sarcomatoid RCC, and clear cell RCC with and without a mutation of the VHL gene. They also found changes specific to both low-grade and high-grade clear cell carcinoma tumors. The DNA changes have to do with the number of copies of different chromosomes found in tumor cells, which researchers found was different from normal cells and among different types of RCC.

Teh said that the DNA changes they found could also lead to potential drug targets. "Each type of RCC is believed to be caused by something different," said Teh, "so ideally, different targets and therapeutic strategies should be selected for each subtype for effective treatment."

According to the American Cancer Society, RCC is the most common type of kidney cancer. In the United States, approximately 54,000 new cases of RCC are diagnosed and 13,000 deaths attributed to the disease each year.

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process.


'/>"/>
SOURCE Van Andel Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention
2. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
3. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Study Findings Show Infection Control Intervention Helps Keep Kids in School
6. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
9. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
10. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
11. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... BRUSSELS , Dec. 2, 2016  UCB is pleased to ... presentation at the upcoming 70 th American Epilepsy Society ... Houston, TX , USA. 1-12 ... safety and efficacy profile of VIMPAT ® (lacosamide) CV ... also share findings on the current state of the union ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):